Pharmacokinetic evaluation and antitumor activity of 2-methoxyestradiol nanosuspension

Drug Development and Industrial Pharmacy

Volumn 38, Issue 4, 2012, Pages 431-438

  Du, Shuzhang ^a   Zhu, Ling ^b   Du, Bin ^b   Shi, Xiufang ^b   Zhang, Zhenzhong ^b   Wang, Shuyu ^b   Zhang, Chaofeng ^b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

2 Methoxyestradiol; Antitumor; Cytotoxicity; Nanosuspension; Pharmacokinetics

Indexed keywords

2 METHOXYESTRADIOL;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PARTICLE SIZE; PHARMACOKINETICS; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; ESTRADIOL; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NANOPARTICLES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SUSPENSIONS; TUMOR CELLS, CULTURED;

EID: 84863276793     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.609560     Document Type: Article

References (53)

1. Akers MJ. (2002). Excipient-drug interactions in parenteral formulations. j Pharm Sci, 91:2283-2300. (Pubitemid 35231192)
2. Ben-Harari RR, Amit T, Youdim MB. (1983). Binding of oestradiol, progesterone and prolactin in rat lung. j Endocrinol, 97:301-310. (Pubitemid 13079816)
3. Bernhard HL, Bohm Muller RH. (1999). Lab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugs. Pharm Sci Tech Today, 2:336-339.
4. Brannon-Peppas L, Blanchette JO. (2004). Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev, 56:1649-1659. (Pubitemid 39177694)
5. Chandana M, Sanjeeb K S. (2010). The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials, 31:6597-6611.
6. Chavanpatil MD, Patil Y, Panyam J. (2006). Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Int j Pharm, 320:150-156. (Pubitemid 44128700)
7. Du B, Li XT, Zhao Y, A YM, Zhang ZZ. (2010). Preparation and characterization of freeze-dried 2-methoxyestradiol nanoparticle powders. Pharmazie, 65:471-476.
8. Du B, Li Y, Li XT, A YM, Zhang ZZ. (2009). LC with fluorescence detection for the tissue pharmacokinetics of 2-methoxyestradiol solution and liposome after intravenous administrations to rats. Chromatographia, 70:1287-1290.
9. Floyd AG. (1999). Top ten considerations in the development of parenteral emulsions. Pharm Sci Technol Today, 4:134-143. (Pubitemid 29195746)
10. Ganta S, Paxton JW, Baguley BC, Garg S. (2009). Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int j Pharm, 367:179-186.
11. Gao S, Fan G, Hong Z, Yin X, Yang S, Wu Y. (2006). HPLC determination of polydatin in rat biological matrices: application to pharmacokinetic studies. j Pharm Biomed Anal, 41:240-245.
12. Gao L, Zhang D, Chen M, Duan C, Dai W, Jia L et al. (2008). Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int j Pharm, 355:321-327.
13. Hany SM, Peter Y, Nicholas B. (2009). Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors. Int J Pharm, 375:107-113.
14. Hecq J, Deleers M, Fanara D, Vranckx H, Boulanger P, Le Lamer S et al. (2006). Preparation and in vitro/in vivo evaluation of nanosized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base. Eur j Pharm Biopharm, 64:360-368. (Pubitemid 44585201)
15. Hintz RJ, Johnson KC. (1989). The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm, 51:9-17. (Pubitemid 19087827)
16. Jabr-Milane LS, van Vlerken LE, Yadav S, Amiji MM. (2008). Multifunctional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev, 34:592-602.
17. James J, Murry DJ, Treston AM, Storniolo AM, Sledge GW, Sidor C et al. (2007). Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs, 25:41-48. (Pubitemid 44657641)
18. Jouyban A. (2007). In silico prediction of drug solubility in waterdioxane mixtures using the Jouyban-Acree model. Pharmazie, 62:46-50. (Pubitemid 46173974)
19. Kesisoglou F, Panmai S, Wu Y. (2007). Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev, 59:631-644. (Pubitemid 47285408)
20. Kipp JE. (2004). The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int j Pharm, 284:109-122. (Pubitemid 39349144)
21. Kyung DL. (1992). Recognition of liposomes by cells: In vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density. Biochimica et Biophys. Acta (BBA)-Biomembranes, 1103:185-197.
22. Lawrence MJ, Rees GD. (2000). Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev, 45:89-121.
23. Lipinski CA. (2001). Avoiding investment in doomed drugs. Is poor solubility an industry wide problem? Curr Drug Discov, 1:17-19.
24. Lipinski C A. (2002). Poor aqueous solubility-an industry wide problem in drug discovery. Am Pharm Rev, 5:82-85.
25. Loftsson T, Brewster ME. (1996). Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. j Pharm Sci, 85:1017-1025. (Pubitemid 26338912)
26. Lou H, Zhang X, Gao L, Feng F, Wang J, Wei X et al. (2009). In vitro and in vivo antitumor activity of oridonin nanosuspension. Int j Pharm, 379:181-186.
27. Lu B. (2005). New techniques and new dosage forms of drugs, 2nd ed., Bei Jing People's Medical Publishing House, 158-167
28. Mattheolabakis G, Taoufik E, Haralambous S, Roberts ML, Avgoustakis K. (2009). In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles. Eur j Pharm Biopharm, 71:190-195.
29. Merisko-Liversidge E, Liversidge GG, Cooper ER. (2003). Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur j Pharm Sci, 18:113-120. (Pubitemid 36184748)
30. Moghimi SM, Hunter AC, Murray JC. (2001). Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev, 53:283-318. (Pubitemid 32476118)
31. Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. j Immunol Methods, 65:55-63. (Pubitemid 14203433)
32. Mukherjee S, Ghosh RN, Maxfield FR. (1997). Endocytosis. Physiol Rev, 77:759-803. (Pubitemid 27328740)
33. Müller RH, Jacobs C, Kayser O. (2001). Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev, 47:3-19. (Pubitemid 32209229)
34. Muller RH, Keck CM. (2004). Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. j Biotechnol, 113:151-170. (Pubitemid 39237077)
35. Müller RH, Keck CM. (2007). Improvement of delivery & solubility of poorly soluble drugs by nanonisation. LTS Academy, Petersberg, p. 12-17.
36. Müller RH, Peters K, Becker R, Kruss B. (1995). Nanosuspensions for the i.v. administration of poorly soluble drugs-stability during sterilization and long-term storage. 22nd International Symposium of Controlled Release of Bioactive Materials, Washington DC, 574-575.
37. Müller RH, Peters K. (1998). Nanosuspensions for the formulation of poorly soluble drugs: preparation by a size reduced technique. Int J Pharm, 160:229-237. (Pubitemid 28083096)
38. Nakano M. (2000). Places of emulsions in drug delivery. Adv Drug Deliv Rev, 45:1-4.
39. Pace SN, Pace GW, Parikh I, Mishra AK. (1999). Novel injectable formulations of insoluble drugs. Pharm Technol, 23:116-134. (Pubitemid 29135950)
40. Patravale VB, Date AA, Kulkarni RM. (2004). Nanosuspensions: a promising drug delivery strategy. j Pharm Pharmacol, 56:827-840. (Pubitemid 38885975)
41. Peters K, Leitzke S, Diederichs JE, Borner K, Hahn H, Müller RH et al. (2000). Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. j Antimicrob Chemother, 45:77-83. (Pubitemid 30060237)
42. Rabinow BE. (2004). Nanosuspensions in drug delivery. Nat Rev Drug Discov, 3:785-796. (Pubitemid 39242830)
43. Radtke M. (2001). NanopureTM pure drug nanoparticles for the formulation of porly soluble drugs. New Drugs, 3:62-68.
44. Rieux A, des Fievez V, Garinot M, Schneider YJ, Préat V. (2006). Nanoparticles as potential oral delivery systems of proteins and vaccines: amechanistic approach. J Control Release, 116:1-27. (Pubitemid 44792295)
45. Shailendra SR, Prahlad CG. (2008). Effect of surface charge and density of distearylphosphatidylethanolamine-mPEG-2000 (DSPE-mPEG-2000) on the cytotoxicity of liposome-entrapped ricin: Effect of lysosomotropic agents. Int J Pharm, 350:79-94.
46. Stegemann S, Leveiller F, Franchi D, de Jong H, Lindén H. (2007). When poor solubility becomes an issue: from early stage to proof of concept. Eur j Pharm Sci, 31:249-261. (Pubitemid 47079001)
47. Stella VJ, Rajewski RA. (1997). Cyclodextrins: their future in drug formulation and delivery. Pharm Res, 14:556-567. (Pubitemid 27220271)
48. Stovall DM, Givens C, Keown S, Hoover KR, Barnes R, Harris C, Lozano J, Nguyen M, Rodriguez E, Acree JWE, Abraham MH. (2005). Solubility of crystalline nonelectrolyte solutes in organic solvents: mathematical correlation of 4-chloro-3-nitrobenzoic acid and 2-chloro-5-nitrobenzoic acid solubilities with the abraham solvation parameter model. Phys Chem Liq, 43:351-360. (Pubitemid 41372317)
49. Sun W, Mao S, Shi Y, Li LC, Fang L. (2011). Nanonization of itraconazole by high pressure homogenization: stabilizer optimization and effect of particle size on oral absorption. j Pharm Sci, 100:3365-3373.
50. Watts AB, McConville JT, Williams RO. (2008). Current therapies and technological advances in aqueous aerosol drug delivery. Drug Dev Ind Pharm, 34:913-922.
51. Wu L, Tang C, Yin C. (2010). Folate-mediated solid-liquid lipid nanoparticles for paclitaxel-coated poly(ethylene glycol). Drug Dev Ind Pharm, 36:439-448.
52. Zhang J, Chen XG, Sun GZ, Huang L, Cheng XJ. (2010). Effect of molecular weight on the oleoyl-chitosan nanoparticles as carriers for doxorubicin. Colloids Surf b Biointerfaces, 77: 125-130.
53. Zhang X, Huang H, Xu Z, Zhan R. (2010). 2-Methoxyestradiol blocks cell-cycle progression at the G2/M phase and induces apoptosis in human acute T lymphoblastic leukemia CEM cells. Acta Biochim Biophys Sin (Shanghai), 42:615-622.